Boehringer-Ingelheim
Encyclopedia
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne
.
Albert Boehringer purchases a small tartar factory in Ingelheim am Rhein.
1886
Albert Boehringer launches the production of tartaric acid
for use in the food industry (e.g. in baking powder and fizzy lemonade).
1895
Lactic acid is manufactured on an industrial scale, proving highly successful on the market over the following years and making C.H. Boehringer Sohn (CHBS) one of the pioneers of biotechnological processes in industrial applications.
1917
The research department is founded on the initiative of the chemist and future Nobel Prize winner for chemistry Prof. Heinrich Wieland (1877 – 1957), a cousin of Albert Boehringer.
1928
Councillor of commerce Albert Boehringer takes over the company Dr. Karl Thomae, based in Winnenden near Stuttgart.
1946
Dr. Karl Thomae GmbH is re-established in Biberach an der Riss with a workforce of 70 people.
1955
The Animal Health division is set up as the company takes over Pfizer’s veterinary programme.
1971
The foreign subsidiary Boehringer Ingelheim Pharmaceuticals, Inc. is founded in Ridgefield, Connecticut (USA), and expanded to become the company’s North American research centre.
1981
Boehringer Ingelheim KG is founded for operations in Germany.
C. H. Boehringer Sohn becomes the holding company for companies in Germany, while the newly formed Boehringer Ingelheim International GmbH becomes the holding company for companies abroad.
1985
The Institute for Molecular Pathology (IMP) is established in Vienna as a joint venture with Genentech, Inc. (USA). The institute opens in 1988. Since 1993, the IMP has been solely owned by Boehringer Ingelheim.
1986
The biotechnological centre in Biberach starts production. Following investment of around DM 150 million (approximately 77 million euro), it is Europe’s largest plant for the production of biopharmaceuticals from cell cultures to date.
1998
Boehringer Ingelheim KG and Dr. Karl Thomae GmbH merge to form Boehringer Ingelheim Pharma KG.
2003
Boehringer Ingelheim invested more than EUR 255 million in the expansion of its biopharmaceutical
active ingredient production facilities in Biberach, the corporation's largest single investment to date.
2010
Boehringer Ingelheim celebrates its 125th anniversary.
Boehringer Ingelheim's Pharma Chemicals business has pioneered the commercial production of monomers and biodegradable polymers for more than 20 years.
safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative
of EFPIA and the European Commission
.
In December 2008, the Boehringer Ingelheim group of companies had 41,300 employees worldwide. Of these, about 30% worked in production, 39% in marketing and sales, and 16.5% in research and development. In 2005, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times'
100 Best Companies To Work For. In 2006 the Science magazine (US)
listed Boehringer Ingelheim as second place for top employers in the biotechnology and pharmaceutical industries.
In 2010, the Boehringer Ingelheim group of companies had 42,224 employees worldwide. Of these, 12,647 worked in production, 16,543 in marketing and sales, and 7,093 in research and development. In Germany
, Brazil
, the Netherlands
, and the United Kingdom
, Boehringer Ingelheim received recognition as one of the best employers for the year 2009. In 2009 the English newspaper ‘Sunday Times’ placed the company in the list ‘Best Places to Work’. The ‘Workforce Diversity Magazine’ and the ‘Careers & the disABLED Magazine’ placed Boehringer Ingelheim as “A Top 50 Employer, Reader’s Choice: 2009”.
Charlemagne
Charlemagne was King of the Franks from 768 and Emperor of the Romans from 800 to his death in 814. He expanded the Frankish kingdom into an empire that incorporated much of Western and Central Europe. During his reign, he conquered Italy and was crowned by Pope Leo III on 25 December 800...
.
History
1885Albert Boehringer purchases a small tartar factory in Ingelheim am Rhein.
1886
Albert Boehringer launches the production of tartaric acid
Tartaric acid
Tartaric acid is a white crystalline diprotic organic acid. It occurs naturally in many plants, particularly grapes, bananas, and tamarinds; is commonly combined with baking soda to function as a leavening agent in recipes, and is one of the main acids found in wine. It is added to other foods to...
for use in the food industry (e.g. in baking powder and fizzy lemonade).
1895
Lactic acid is manufactured on an industrial scale, proving highly successful on the market over the following years and making C.H. Boehringer Sohn (CHBS) one of the pioneers of biotechnological processes in industrial applications.
1917
The research department is founded on the initiative of the chemist and future Nobel Prize winner for chemistry Prof. Heinrich Wieland (1877 – 1957), a cousin of Albert Boehringer.
1928
Councillor of commerce Albert Boehringer takes over the company Dr. Karl Thomae, based in Winnenden near Stuttgart.
1946
Dr. Karl Thomae GmbH is re-established in Biberach an der Riss with a workforce of 70 people.
1955
The Animal Health division is set up as the company takes over Pfizer’s veterinary programme.
1971
The foreign subsidiary Boehringer Ingelheim Pharmaceuticals, Inc. is founded in Ridgefield, Connecticut (USA), and expanded to become the company’s North American research centre.
1981
Boehringer Ingelheim KG is founded for operations in Germany.
C. H. Boehringer Sohn becomes the holding company for companies in Germany, while the newly formed Boehringer Ingelheim International GmbH becomes the holding company for companies abroad.
1985
The Institute for Molecular Pathology (IMP) is established in Vienna as a joint venture with Genentech, Inc. (USA). The institute opens in 1988. Since 1993, the IMP has been solely owned by Boehringer Ingelheim.
1986
The biotechnological centre in Biberach starts production. Following investment of around DM 150 million (approximately 77 million euro), it is Europe’s largest plant for the production of biopharmaceuticals from cell cultures to date.
1998
Boehringer Ingelheim KG and Dr. Karl Thomae GmbH merge to form Boehringer Ingelheim Pharma KG.
2003
Boehringer Ingelheim invested more than EUR 255 million in the expansion of its biopharmaceutical
Biopharmaceutical
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins , nucleic acids and living microorganisms like virus and bacteria where the virulence of viruses and bacteria is reduced by the process of attenuation, they can be used for therapeutic or in vivo diagnostic...
active ingredient production facilities in Biberach, the corporation's largest single investment to date.
2010
Boehringer Ingelheim celebrates its 125th anniversary.
Fields of activity
The business areas consist of Human Pharmaceuticals and Animal Health. In 2010, 42,224 employees were in 145 affiliated companies worldwide, research and development (R&D) facilities were in seven sites and 20 production plants in 13 countries.Boehringer Ingelheim's Pharma Chemicals business has pioneered the commercial production of monomers and biodegradable polymers for more than 20 years.
Collaborative research
In addition to internal research and development activities Boehringer Ingelheim is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinicalPre-clinical development
In drug development, pre-clinical development is a stage of research that begins before clinical trials can begin, and during which important feasibility, iterative testing and drug safety data is collected....
safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative
Innovative Medicines Initiative
The Innovative Medicines Initiative is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research...
of EFPIA and the European Commission
European Commission
The European Commission is the executive body of the European Union. The body is responsible for proposing legislation, implementing decisions, upholding the Union's treaties and the general day-to-day running of the Union....
.
Operational/development sites
The company's largest site and corporate headquarters is located in Ingelheim am Rhein near Mainz and Frankfurt, Germany. However, Boehringer Ingelheim is a globally-operating company, with 145 subsidiaries around the globe. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology[5] in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.In December 2008, the Boehringer Ingelheim group of companies had 41,300 employees worldwide. Of these, about 30% worked in production, 39% in marketing and sales, and 16.5% in research and development. In 2005, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times'
The Sunday Times (UK)
The Sunday Times is a Sunday broadsheet newspaper, distributed in the United Kingdom. The Sunday Times is published by Times Newspapers Ltd, a subsidiary of News International, which is in turn owned by News Corporation. Times Newspapers also owns The Times, but the two papers were founded...
100 Best Companies To Work For. In 2006 the Science magazine (US)
Science (journal)
Science is the academic journal of the American Association for the Advancement of Science and is one of the world's top scientific journals....
listed Boehringer Ingelheim as second place for top employers in the biotechnology and pharmaceutical industries.
In 2010, the Boehringer Ingelheim group of companies had 42,224 employees worldwide. Of these, 12,647 worked in production, 16,543 in marketing and sales, and 7,093 in research and development. In Germany
Germany
Germany , officially the Federal Republic of Germany , is a federal parliamentary republic in Europe. The country consists of 16 states while the capital and largest city is Berlin. Germany covers an area of 357,021 km2 and has a largely temperate seasonal climate...
, Brazil
Brazil
Brazil , officially the Federative Republic of Brazil , is the largest country in South America. It is the world's fifth largest country, both by geographical area and by population with over 192 million people...
, the Netherlands
Netherlands
The Netherlands is a constituent country of the Kingdom of the Netherlands, located mainly in North-West Europe and with several islands in the Caribbean. Mainland Netherlands borders the North Sea to the north and west, Belgium to the south, and Germany to the east, and shares maritime borders...
, and the United Kingdom
United Kingdom
The United Kingdom of Great Britain and Northern IrelandIn the United Kingdom and Dependencies, other languages have been officially recognised as legitimate autochthonous languages under the European Charter for Regional or Minority Languages...
, Boehringer Ingelheim received recognition as one of the best employers for the year 2009. In 2009 the English newspaper ‘Sunday Times’ placed the company in the list ‘Best Places to Work’. The ‘Workforce Diversity Magazine’ and the ‘Careers & the disABLED Magazine’ placed Boehringer Ingelheim as “A Top 50 Employer, Reader’s Choice: 2009”.
Key product lines
Aggrenox, Antistax, Bisolvon, Buscopan, Buscapina, CircoFLEX, Dulcolax, Duramune, Flomax, Metacam, Micardis + Micardis Plus, Mirapex, Mucosolvan, Mucoangin, Mobic, Spiriva, Pharmaton, Pradaxa, Resomer, Vetmedin, Viramune, Zantac, Twynsta.External links
- Boehringer Ingelheim Corporate website
- Boehringer Ingelheim Vetmedica United States Animal Health website
- Boehringer Ingelheim German website
- Boehringer Ingelheim USA website
- News-Centre (for journalists)
- Social Media at Boehringer Ingelheim
- CHC Products
- Boehringer Ingelheim Italia
- Boehringer Ingelheim Argentina
- Boehringer Ingelheim (Canada) Ltd.
- Boehringer Ingelheim Brazil
- Boehringer Ingelheim Spain
- Boehringer Ingelheim Mexico
- Site Buscopan Brazil